Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Amicus Therapeutics Earnings Preview ↗

February 23, 2022

Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

January 14, 2022

Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022 ↗

January 14, 2022

Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher ↗

January 10, 2022

Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S....

Via Benzinga

Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge ↗

January 10, 2022

Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

45 Stocks Moving In Monday's Mid-Day Session ↗

January 10, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 ↗

November 15, 2021

Upgrades For Targa Resources Corp (NYSE:

Via Benzinga

Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

FOLD earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Week In SPAC News - Sunday, Oct. 3 ↗

October 03, 2021

In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.

Via Talk Markets

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business ↗

September 29, 2021

Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗

September 30, 2021

Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...

Via Benzinga

Why Are Amicus Therapeutics Shares Trading Higher Today? ↗

September 29, 2021

The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 29, 2021

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 07, 2021

Gainers Cellectar Biosciences (NASDAQ:CLRB

Via Benzinga

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021? ↗

August 12, 2021

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Via The Motley Fool

Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

FOLD earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents ↗

August 02, 2021

The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable...

Via Benzinga

14 Biotech Stocks To Watch Over The Next 6 Months ↗

June 23, 2021

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...

Via Benzinga

Amicus Therapeutics Insights: Return On Capital Employed ↗

June 23, 2021

Amicus Therapeutics (NASDAQ:FOLD) reported Q1 sales of $66.40 million. Earnings fell to a loss of $52.58 million, resulting in a 18.31% decrease from last quarter. In Q4, Amicus...

Via Benzinga

Looking Into Amicus Therapeutics's Return On Capital Employed ↗

June 07, 2021

During Q1, Amicus Therapeutics (NASDAQ:FOLD) brought in sales totaling $66.40 million. However, earnings decreased 18.31%, resulting in a loss of $52.58 million. In Q4, Amicus...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 27, 2021

Gainers Cellect Biotechnology (NASDAQ:APOP

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021 ↗

May 27, 2021

Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80...

Via Benzinga

The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing ↗

May 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...

Via Benzinga

Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript ↗

May 10, 2021

FOLD earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal ↗

May 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 ↗

May 21, 2021

Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.